Skip to main content
EVO
NASDAQ Life Sciences

Activist Investor MAK Capital Reaches Cooperation Agreement with Evotec SE, Securing Board Nomination

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
7
Price
$3.09
Mkt Cap
$1.092B
52W Low
$2.308
52W High
$4.8
Market data snapshot near publication time

summarizeSummary

Activist investor MAK Capital Fund LP, holding 7.1% of Evotec SE, has entered into a cooperation agreement with the company, leading to a board nomination and mutual voting commitments.


check_boxKey Events

  • Cooperation Agreement Signed

    MAK Capital Fund LP and Evotec SE entered into a cooperation agreement on April 29, 2026, formalizing their relationship and future actions.

  • Board Nomination Secured

    Evotec SE will nominate Dr. Wolfgang Hofmann as an independent member to the Supervisory Board at the upcoming Annual General Meeting on June 11, 2026.

  • Shareholder Voting Commitments

    MAK Fund has agreed to customary voting and cooperation commitments, including supporting the board expansion to seven members and the three candidates nominated by the Issuer.

  • Increased Stake to 7.1%

    MAK Capital Fund LP now beneficially owns 12,681,898 shares, representing approximately 7.1% of Evotec SE's outstanding shares, following recent purchases valued at approximately $7.38 million.


auto_awesomeAnalysis

This Schedule 13D/A filing confirms a significant development where activist investor MAK Capital Fund LP has reached a cooperation agreement with Evotec SE. The agreement, previously announced by the company in a 6-K filing on April 30, 2026, includes the nomination of Dr. Wolfgang Hofmann as an independent member to the Supervisory Board. This signals a constructive resolution between a major shareholder and the company, potentially avoiding future disputes and enhancing corporate governance. MAK Capital Fund LP also disclosed recent open market purchases totaling approximately $7.38 million, increasing their stake to 7.1%.

At the time of this filing, EVO was trading at $3.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.31 to $4.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed EVO - Latest Insights

EVO
May 01, 2026, 5:01 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
EVO
Apr 30, 2026, 11:48 AM EDT
Filing Type: 6-K
Importance Score:
7
EVO
Apr 24, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
7
EVO
Apr 08, 2026, 11:56 AM EDT
Filing Type: 6-K
Importance Score:
8
EVO
Apr 08, 2026, 11:52 AM EDT
Filing Type: 20-F
Importance Score:
8
EVO
Apr 07, 2026, 12:44 PM EDT
Filing Type: 6-K
Importance Score:
9
EVO
Apr 06, 2026, 12:56 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
EVO
Mar 30, 2026, 8:29 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
EVO
Mar 10, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
9
EVO
Jan 16, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7